{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Table 1:', 'Schedule of Activities: Screening Through End of the Randomized-Controlled Period (Continued)', 'Clinical', 'Period/Phase', 'Screening', 'Randomized-Controlled Period', 'Deterioration\u00b9', 'Study Visit', '1', '2', '3', '4', '5', '6', '7', '8', '9/ET2', 'Study Day', 'D1', 'D8', 'D15', 'D29', 'D71', 'D85', 'D127', 'D183', 'Window (day)', '+2', '2', ' 2', '+ 2', '2', '+ 2', ' 2', 'Weeks', '-4 to -2 W', 'W1', 'W2', 'W4', 'W10', 'W12', 'W18', 'W26', 'Clinical Lab Tests10', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Pregnancy Test 11', 'X', 'X', 'X', 'X', 'X', 'X', 'PK, Free C512', 'B/P', 'T/P', 'T/P', 'T/P', 'T', 'X', 'ADA 13', 'X', 'X', 'X', 'X', 'X', 'N meningitidis Vaccine1', 'X', 'Patient Safety Information', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Card14', 'Randomization15', 'X', 'Study Drug Infusion\u00b9 16', 'X', 'X', 'X', 'X', '1', 'Evaluation of Clinical Deterioration must be performed as soon as possible, within 48 hours of notification to the Investigator of symptom onset. If Clinical', 'Deterioration occurs between scheduled visits, only the assessments for the Clinical Deterioration visit are needed. If Clinical Deterioration', 'occurs', 'on', 'a', 'scheduled visit, all scheduled assessments should be performed for that visit as well as for the evaluation of Clinical Deterioration.', 'Additional', 'evaluation', 'visits', 'may be scheduled at the discretion of the Investigator.', '2', 'If a patient withdraws early from the study during the Randomized-Controlled Period, an Early Termination Visit will be', 'performed.', '3', 'MG history will include diagnosis date; initial MG clinical presentation (oMG or gMG); time to gMG, if initial clinical presentation was oMG; maximum', 'MGFA classification since diagnosis; ventilatory support since diagnosis; dates of MG exacerbation or crisis since diagnosis and prior to Day 1; and any MG-', 'related hospitalizations in 2 years prior to screening. MG-specific medication or therapy taken within 2 years prior to screening will be recorded.', '4', 'Refer to Section 4.2.4.', '5', 'Vital signs and pulse oximetry will include systolic and diastolic blood pressure (millimeters of mercury [mmHg]), pulse oximetry (oxygen saturation [SO2]),', 'heart rate (beats/minute), and temperature (degrees Celsius [\u00b0C] or degrees Fahrenheit [\u00b0F]). On dosing days, vital signs will be taken before study drug', 'administration and after the patient has been resting for at least 5 minutes.', \"6 To be performed, if necessary, on the basis of the patient's health status and the clinical judgment of the Investigator.\", '7 The MG-ADL is required to be performed first, followed by the QMG. The MG-activities of daily living (MG-ADL) assessment should be performed by a', 'Properly Trained Clinical Evaluator (as defined in the study protocol), preferably the same evaluator, throughout the study. The recall period for MG-ADL is', 'the preceding 7 days or since the last visit if the visit interval is less than 7 days.', '8', 'The QMG and MGC assessments should be performed by a Properly Trained Clinical Evaluator (as defined in the study protocol), preferably the same', 'evaluator, throughout the study. If a patient is taking a cholinesterase inhibitor, the dose must be withheld for at least 10 hours prior to the assessment.', '9', 'C-SSRS will be assessed for both lifetime and past 1 year (12 months).', '10 Clinical laboratory tests will be performed at the central laboratory.', 'Page 21 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Table 1:', 'Schedule of Activities: Screening Through End of the Randomized-Controlled Period (Continued)', '11', 'Pregnancy tests must be performed on all patients of child-bearing potential at the specified time points. Serum pregnancy test will be performed at Screening', 'and Day 183/ET; urine pregnancy tests will be performed locally at all other required time points. A negative urine test result performed locally is required', 'prior to administering ravulizumab to patients of childbearing potential at the indicated visits. Additional pregnancy tests (urine or serum) may also be', \"performed at any visit at the Investigator's discretion.\", '12 Baseline (B) and trough (T) blood samples for serum PK, free C5 (PD), and ADA will be collected predose (within 30 minutes prior to the start of infusion of', 'study drug). Peak (P) blood samples for serum PK/PD samples are to be taken within the 30 minutes following completion of study drug infusion. The T', 'samples may be drawn through the venous access created for the dose infusion, prior to administration of the dose. The P samples will be drawn from the', \"patient's opposite, noninfused arm. On Day 183 (Week 26), the T sample is considered a Randomized-Controlled Period assessment and the P sample is\", 'considered an Extension Period assessment. All collection times will be recorded in eCRF. In the event of Clinical Deterioration, blood samples for serum', 'PK/PD and ADA analyses will be collected if supplemental dosing is provided (see Section 8.1.2).', '13 To reduce the risk of meningococcal infection (N meningitidis), all patients must be vaccinated against meningococcal infections within 3 years prior to, or at', 'the time of, initiating study drug. Patients who initiate study drug treatment less than 2 weeks after receiving a meningococcal vaccine must receive treatment', 'with appropriate prophylactic antibiotics until 2 weeks after vaccination.', '14 Patients will be given a Patient Safety Information Card prior to the first dose of study drug. At each visit throughout the study, the study staff will ensure that', 'the patient has the Patient Safety Information Card.', '15 All patients that continue to meet all inclusion criteria and none of the exclusion criteria and have been cleared for randomization by the Investigator will be', 'centrally randomized through interactive response technology (IRT).', '16', 'Study drug will be administered intravenously via infusion after completion of all other tests and procedures, excluding the peak blood sampling for PK/PD,', 'free C5, and ADA.', 'Abbreviations: AChR Ab = acetylcholine receptor antibody; ADA = antidrug antibody; B = baseline sample; C5 = complement component 5;', 'C-SSRS = Columbia-Suicide Severity Rating Scale; D = day; ECG = electrocardiogram; EQ-5D-5L=Euro Quality of Life; ET = Early Termination;', 'HIV = Human Immunodeficiency Virus; MG = Myasthenia Gravis; MG-ADL = Myasthenia gravis Activities of Daily Living profile; MGC = Myasthenia gravis', 'Composite score; MGFA = Myasthenia Gravis Foundation of America; MGFA-PIS = MGFA-Post-Intervention Status; N meningitidis = Neisseria meningitidis;', 'P', '= peak sample; PK/PD = = pharmacokinetic(s)/pharmacodynamic(s); QMG = Quantitative Myasthenia Gravis score for disease severity; QoL = quality of life;', 'T = trough sample; W = week(s).', 'Page 22 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}